SAPPORO CLINICAL LABORATORY INC.
札幌臨床検査センター株式会社
Valuation
Fundamental ratios for the latest reported period.
Ticker: 9776
FY2024 (Mar 2025) · J-GAAP · consolidated Source: filing S100W42N
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2024 (Mar 2025) runs Apr 1, 2024 – Mar 31, 2025.
| Gross margin | 30.5% |
|---|---|
| Operating margin | 3.5% |
| Net margin | 2.3% |
| Return on equity | 4.2%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | 2.8% |
| Revenue growth (YoY) | 2.3% |
| EPS (basic) | ¥148.35 |
| EPS growth (YoY) | 30.0% |
| Current ratio | 2.13x |
| Equity ratio | 67.8% |
| Book value / share | ¥3,575.27 |
| Free cash flow | −¥546M |